
WHAT IS CLAIMED IS:

1. A compound represented by Formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein:

X is CR^5 or N;

G^1 is N or CR^{G1};

G^2 is CR^{G2} or N;

G^3 is CR^{G3} or N;

G^4 is CR^{G4} or N;

G^5 is CR^{G5} or N;

R^{G1} is selected from the group consisting of H, C_{1-3} alkyl, halogen, C_{1-3} haloalkyl, and CN;

each R^{G2}, R^{G3}, R^{G4} and R^{G5} is independently selected from the group consisting of H, halo, CN, C_{1-7} alkyl, C_{3-7} cycloalkyl, C_{1-3} haloalkyl, -O-C_{1-3} alkyl, -O-C_{1-3} haloalkyl, -NR^aR^b, and 5- to 8-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein cycloalkyl and heterocycloalkyl are substituted with 0-3 groups independently selected from halo, CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, -O-C_{1-4} alkyl, and OH;

A is a fused ring selected from the group consisting of cycloheptane, cyclohexane, cyclopentane, azepane, 1,4-oxazepane, 1,4-diazepane, oxepane, tetrahydropyran, piperidine, bicyclo[4.2.1]nonane, bicyclo[4.1.1]octane, spiro[4.6]undecane, 1-azaspiro[4.6]undecane, and cyclooctane, each of which is substituted with from 1 to 4 R^2, and further substituted with 0 or 1 oxo (=O) which is on a carbon atom adjacent to a nitrogen atom;

R^1 is selected from the group consisting of phenyl and a 5 to 6-membered heteroaryl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each phenyl and heteroaryl is substituted with one R^{1a} and 0-3 R^3;

R^{1a} is selected from the group consisting of phenyl and a 5 to 6-membered heteroaryl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the N atom, when present, is optionally oxidized, and wherein each phenyl and heteroaryl is substituted with 0-4 R^4;

each R^2 is independently selected from the group consisting of C_{1-7} alkyl, C_{3-7} alkenyl, C_{3-7} alkynyl, C_{3-7} cycloalkyl, -Y^1-O-C_{1-7} alkyl, -Y^1-O-C_{3-7} cycloalkyl, -NR^aR^b, -C(O)-C_{1-7} alkyl, -C(O)-C_{3-7} cycloalkyl, -$S(O)_2$-C_{1-7} alkyl, -$S(O)_2$-C_{3-7} cycloalkyl, -$C(O)NR^aR^b$, 5- to 8-membered heterocycloalkyl, -NR^a-(5- to 8-membered heterocycloalkyl), -C(O)-(5- to 8-membered heterocycloalkyl), -X^1-5- to 8-membered heterocycloalkyl, and -O-X^1-(5- to 8-membered heterocycloalkyl), wherein the heterocycloalkyl has 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each cycloalkyl and heterocycloalkyl is substituted with from 0-3 groups independently selected from halo, CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, -O-C_{1-4} alkyl, and OH;

each R^3 is independently selected from the group consisting of halogen, CN, C_{1-7} alkyl, C_{2-7} alkenyl, C_{3-7} alkynyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} halohydroxyalkyl, -O-C_{1-7} alkyl, -O-C_{1-6} haloalkyl, -NR^aR^b, -C(O)-NR^aR^b, -$S(O)_2$-NR^aR^b, -S(O)(NH)-C_{1-7} alkyl, -$S(O)_2$-C_{1-7} alkyl, and -$S(O)_2$-C_{1-7} haloalkyl;

each R^4 is independently selected from the group consisting of C_{1-7} alkyl, halo, C_{1-7} haloalkyl, -O-C_{1-7} alkyl, -O-C_{1-7} haloalkyl, CN, -C_{1-7} alkylene-CN, hydroxy, C_{1-7} hydroxyalkyl, -$C(O)NR^aR^b$, C_{3-7} cycloalkyl, -NR^a-C(O)-C_{1-7} alkyl, -NR^a-C(O)-C_{3-7} cycloalkyl, -NR^aR^b, -O-C_{1-4} alkylene-O-C_{1-4} alkyl, -O-(5- to 8-membered heterocycloalkyl) having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, -5- to 8-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, -$S(O)_2$-C_{1-7} alkyl, -$S(O)_2$-C_{3-7} cycloalkyl, -$S(O)_2$-NR^aR^b, -NR^a-$S(O)_2$-C_{1-7} alkyl, and -NR^a-$S(O)_2$-C_{3-7} cycloalkyl, wherein each cycloalkyl and heterocycloalkyl is substituted with 0 to 2

groups independently selected from the group consisting of C_{1-4} alkyl, halo, and hydroxy;

alternatively, two R^4 groups on the same ring vertex combine to form an oxo (=O); or

two R^4 groups on adjacent ring vertices combine to form a 5- to 6-membered heterocycloalkyl having from 1 to 2 heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the 5- to 6-membered heterocycloalkyl is substituted with 0 to 2 groups independently selected from the group consisting of C_{1-4} alkyl and halo;

R^5 is selected from the group consisting of H, C_{1-4} alkyl, and $–NH_2$;

each X^1 is C_{1-7} alkylene or C_{3-7} cycloalkylene;

each Y^1 is C_{2-7} alkylene or C_{3-7} cycloalkylene;

each R^a and R^b are independently selected from group consisting of H, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-4} alkoxyC_{1-4}alkyl and C_{3-7} cycloalkyl, wherein said cycloalkyl is optionally substituted with -O-C_{1-3} alkyl; or

R^a and R^b together with the nitrogen to which they are attached form a 4- to 8- membered heterocycloalkyl ring having 0-2 additional heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the heterocycloalkyl ring is substituted with 0-3 groups, each group is independently selected from halo, CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, -O-C_{1-4} alkyl, and X^1-O-C_{1-3} alkyl, and OH; or two groups on the same ring vertex combine to form an oxo (=O).

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein:

G^3 is CR^{G3}, and R^{G3} is H;

G^4 is CR^{G4} and R^{G4} is H;


G^5 are each CR^{G5} and R^{G5} is H;

G^1 is N or CR^{G1} wherein R^{G1} is H; and,

G^2 is CR^{G2} and R^{G2} is H.


3. The compound of claim **1** or claim **2**, or a pharmaceutically acceptable salt thereof, wherein X is CR^5 and R^5 is H.

4. The compound of any one of claims **1** to **3**, or a pharmaceutically acceptable salt thereof, wherein A has a formula selected from the group consisting of:




each of which is substituted with from 1 to 4 R^2.

5. The compound of claim **4**, or a pharmaceutically acceptable salt thereof, wherein A has the formula:




6. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein one R^2 is $-NR^aR^b$.

7. The compound of any one of claims **1** to **6**, or a pharmaceutically acceptable salt thereof, wherein one R^2 is selected from the group consisting of:




8. The compound of claim **7**, or a pharmaceutically acceptable salt, wherein one R^2 is



9. The compound of any one of claims **1** to **8**, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxadiazolyl, and pyrazolyl, wherein R^1 is substituted with one R^{1a} and 0-2 R^3.

10. The compound of claim **9**, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:




wherein the subscript p is 0 or 1.

11. The compound of claim **1**, or pharmaceutically acceptable salt thereof, wherein each R^3, when present, is independently selected from the group consisting of halogen, $C_{1\text{-}4}$ alkyl, and -O-$C_{1\text{-}4}$ alkyl.


12. The compound of any one of claims **1** to **11**, or pharmaceutically acceptable salt thereof, wherein R^{1a} is selected from the group consisting of, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl N-oxide, and phenyl, wherein R^{1a} is substituted with and 0-3 R^4.

13. The compound of claim **12**, or pharmaceutically acceptable salt thereof, wherein R^{1a} is selected from the group consisting of:



wherein the subscript q is 0, 1, or 2.

14. The compound of claim **12**, or pharmaceutically acceptable salt thereof, wherein R^{1a} is selected from the group consisting of:




wherein the subscript q is 0, 1, or 2.


15. The compound of any one of claims **1** to **14**, or pharmaceutically acceptable salt thereof, wherein each R^4, when present, is independently selected from the group consisting of C_{1-4} alkyl, halo, C_{1-4} haloalkyl, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, CN, -C_{1-4} alkylene-CN, C_{1-4} hydroxyalkyl, -C(O)NR^aR^b, C_{3-7} cycloalkyl, -NR^a-C(O)-C_{3-7} cycloalkyl, -NR^aR^b, -O-C_{1-4} alkylene-O-C_{1-4} alkyl, -O-(5- to 6-membered heterocycloalkyl) having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, -5- to 8-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, -$S(O)_2$-C_{1-4} alkyl, and -$S(O)_2$-NR^aR^b, wherein each cycloalkyl and heterocycloalkyl is substituted with 0 to 2 groups selected from the group consisting of C_{1-4} alkyl, halo, and hydroxy.

16. The compound of claim **15**, or pharmaceutically acceptable salt thereof, wherein each R^4, when present, is independently selected from the group consisting of methyl,


ethyl, fluoro, chloro, difluoromethyl, trifluoromethyl, CN, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy,




17. The compound of any one of claims **1** to **16**, or a pharmaceutically acceptable salt thereof, having a structure selected from Formula (Ia), or Formula (Ia1). Formula (1b) and Formula (1bI):




(Ia),



(Ia1),




(Ib), and




(Ib1),

wherein for each of Formula (Ib) and Formula (Ib1), the subscript m is 0 or 1; and n is 0, 1 or 2, and each R^2 can be the same or different.

18. The compound of claim **17**, or a pharmaceutically acceptable salt thereof, having a structure of Formula (If) or Formula (If1):
























(If),




























(If1).













19. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
















,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,























































































,

,

,

,

,

,

,

,

,

,

,

,

,

,








































,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

























,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,




20. A compound having the structure:



,

or a pharmaceutically acceptable salt thereof.

21. A compound having the structure:



.

22. A pharmaceutical composition comprising a compound of any one of claims **1**-**21**, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

23. Use of the compound of any one of claims **1-21**, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim **22**, for the manufacture of a medicament for treating a disease, disorder, or condition selected from the group consisting of cancer, fibrosis, a viral infection, and pain.

24. The use of claim **23**, wherein said disease, disorder, or condition is cancer.

25. The use of claim **23** or **24**, wherein the medicament is to be used with at least one additional therapeutic agent to the subject.